Trevor J Orchard1, Jye-Yu C Backlund2, Tina Costacou1, Patricia Cleary2, Maria Lopes-Virella3, Andrew P Levy4, John M Lachin5. 1. Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA. 2. The Biostatistics Center, The George Washington University, Rockville, MD, USA. 3. Medical University of South Carolina, Charleston, SC, USA. 4. Israel Institute of Technology, Haifa, Israel. 5. The Biostatistics Center, The George Washington University, Rockville, MD, USA. Electronic address: jml@bsc.gwu.edu.
Abstract
AIMS/HYPOTHESIS: Haptoglobin(Hp) 2-2 genotype has been shown to increase coronary artery disease (CAD) risk in numerous type 2 diabetes studies but in only one type 1 diabetes cohort. We assessed the association of Hp2-2 with incident CAD over 26years of follow-up in 1303 Caucasian participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. METHODS:DCCT randomized volunteers with type 1 diabetes to intensive versus conventional therapy within two cohorts: 'primary prevention' with1-5years diabetes duration and 'secondary intervention' with 1-15years diabetes duration and early retinopathy, with or without albuminuria, but no advanced complications. CAD was defined as myocardial infarction (MI) or death judged to be from CAD, silent MI, angina, coronary revascularization, or congestive heart failure due to CAD. RESULTS: In the entire DCCTcohort, Hp2-2 was not significantly associated with incident CAD or MI. However, in pre-specified exploratory subgroup analyses, an increased MI risk was suggested in the secondary cohort for those with Hp2-2. CONCLUSIONS/ INTERPRETATION: The analysis does not statistically confirm an overall association between Hp 2-2 and incident CAD, however, some suggestions of associations were observed in secondary analyses.
RCT Entities:
AIMS/HYPOTHESIS: Haptoglobin(Hp) 2-2 genotype has been shown to increase coronary artery disease (CAD) risk in numerous type 2 diabetes studies but in only one type 1 diabetes cohort. We assessed the association of Hp2-2 with incident CAD over 26years of follow-up in 1303 Caucasian participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. METHODS:DCCT randomized volunteers with type 1 diabetes to intensive versus conventional therapy within two cohorts: 'primary prevention' with 1-5years diabetes duration and 'secondary intervention' with 1-15years diabetes duration and early retinopathy, with or without albuminuria, but no advanced complications. CAD was defined as myocardial infarction (MI) or death judged to be from CAD, silent MI, angina, coronary revascularization, or congestive heart failure due to CAD. RESULTS: In the entire DCCTcohort, Hp2-2 was not significantly associated with incident CAD or MI. However, in pre-specified exploratory subgroup analyses, an increased MI risk was suggested in the secondary cohort for those with Hp2-2. CONCLUSIONS/ INTERPRETATION: The analysis does not statistically confirm an overall association between Hp 2-2 and incident CAD, however, some suggestions of associations were observed in secondary analyses.
Authors: Andrew P Levy; Irit Hochberg; Kathleen Jablonski; Helaine E Resnick; Elisa T Lee; Lyle Best; Barbara V Howard Journal: J Am Coll Cardiol Date: 2002-12-04 Impact factor: 24.094
Authors: Petra Ijäs; Jani Saksi; Lauri Soinne; Jarno Tuimala; Matti Jauhiainen; Antti Jula; Mika Kähönen; Y Antero Kesäniemi; Petri T Kovanen; Markku Kaste; Perttu J Lindsberg Journal: Atherosclerosis Date: 2013-07-25 Impact factor: 5.162
Authors: Mahmoud Suleiman; Doron Aronson; Rabea Asleh; Michael R Kapeliovich; Ariel Roguin; Simcha R Meisel; Michael Shochat; Abeer Sulieman; Shimon A Reisner; Walter Markiewicz; Haim Hammerman; Rachel Lotan; Nina S Levy; Andrew P Levy Journal: Diabetes Date: 2005-09 Impact factor: 9.461
Authors: Rabea Asleh; Rachael Miller-Lotan; Michael Aviram; Tony Hayek; Michael Yulish; Joanne E Levy; Benjamin Miller; Shany Blum; Uzi Milman; Chen Shapira; Andrew P Levy Journal: Circ Res Date: 2006-11-02 Impact factor: 17.367
Authors: Rabea Asleh; Alexandros Briasoulis; Elliot M Berinstein; Joshua B Wiener; Mohan Palla; Sudhir S Kushwaha; Andrew P Levy Journal: Pharmgenomics Pers Med Date: 2018-04-23